CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Gantenerumab treatment generated a slowing of clinical decline from baseline score on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), but at levels that did not reach statistical significance. The relative reduction in clinical decline was 8% in GRADUATE I and 6% in GRADUATE II compared with placebo.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
